世界の髄膜炎菌ワクチン市場(2014-2018)

◆英語タイトル:Global Meningococcal Vaccines Market 2014-2018
◆商品コード:IRTNTR3936
◆発行会社(調査会社):Technavio
◆発行日:2014年8月20日
◆ページ数:78
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥319,200見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥399,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

About Meningococcal Vaccines
Meningitis is characterized by the inflammation of the protective lining (meninges) present around the brain and the spinal cord. On the basis of its underlying cause, meningitis can be classified into infectious and non-infectious meningitis. In terms of the type of organism, infectious meningitis can be sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis is the life-threatening form of infectious meningitis, which can occur due to infection by different bacterial species such as Hemophilus influenza, Listeria monocytogenes, Neisseria meningitides, and Streptococcus pneumonia. Bacterial infection can spread to the blood stream, leading to septicemia. An infection by Neisseria meningitides can lead to meningococcal disease, which is associated with the simultaneous occurrence of meningitis and septicemia. Meningococcal disease can occur at any age; however, it is more prevalent in infants and adolescents. Meningococcal disease involves a sudden onset of symptoms which can lead to death within hours, if left untreated. Disease survivors can recover fully or may suffer from long-term after effects such as neurological defects. Meningococcal disease is generally treated with antibiotics. Preventive measures involve the administration of meningococcal vaccines.

TechNavio’s analysts forecast the Global Meningococcal Vaccines market to grow at a CAGR of 15.00 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Meningococcal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the administration of various vaccines to actively immunize meningococcal disease caused by different serogroups of Neisseria meningitides.
TechNavio’s report, the Global Meningococcal Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Meningococcal Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• GlaxoSmithKline
• Novartis
• Sanofi Pasteur

Other Prominent Vendors
• Beijing Minhai Biotechnology
• Bio Med
• Hualan Biological Engineering
• Imunoloski Zavod
• JN International Medical
• Nuron Biotech
• Pfizer
• Serum Institute of India
• Vacunas Finlay

Market Driver
• Designated as Traveler’s Vaccine
• For a full, detailed list, view our report
Market Challenge
• Require Cold Storage
• For a full, detailed list, view our report
Market Trend
• Combination Vaccines
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
05.1 Market Overview
05.2 Market Size and Forecast
05.3 Five Forces Analysis
06. Market Segmentation by Composition
06.1 Mono Vaccine
06.1.1 Polysaccharide Vaccines
06.1.2 Conjugate Vaccines
06.2 Combination Vaccines
07. Geographical Segmentation
08. Key Leading Countries
08.1 US
08.2 Brazil
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.2 Market Share Analysis 2013
16.2.1 GlaxoSmithKline
16.2.2 Sanofi Pasteur
16.2.3 Novartis
16.3 Other Prominent and Future Vendors
17. Late-stage Pipeline Candidates
17.1 Key Information for Late-stage Pipeline Candidates
17.1.1 Bexsero
17.1.2 rLP2086
17.1.3 MCV-ACYW135 Vaccine
18. Key Vendor Analysis
18.1 GlaxoSmithKline
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Pipeline Products
18.1.7 Business Strategy
18.1.8 Key Information
18.1.9 SWOT Analysis
18.2 Novartis
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue 2013
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Business Strategy
18.2.7 Key Developments
18.2.8 SWOT Analysis
18.3 Sanofi Pasteur
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Strategy
18.3.4 Recent Developments
18.3.5 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Meningococcal Vaccines Market 2013-2018 (US$ billion)
Exhibit 3: Global Meningococcal Vaccines Market Segmentation by Composition
Exhibit 4: Global Meningococcal Vaccines Market by Geographical Segmentation 2013
Exhibit 5: Global Meningococcal Vaccines Market Share by Leading Countries 2013
Exhibit 6: GlaxoSmithkline’s Vaccines: Percentage Share in GlaxoSmithKline Turnover 2013
Exhibit 7: Sanofi’s Vaccines: Percentage Share in Sanofi Net Sales 2013
Exhibit 8: Novartis’ Vaccines and Diagnostics: Percentage Share in Novartis Net Sales 2013
Exhibit 9: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 10: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 11: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 12: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 13: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 14: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 15: Novartis AG: Sales by Geography 2013



【掲載企業】

GlaxoSmithKline, Novartis , Sanofi PasteurOther Prominent Vendors, Beijing Minhai Biotechnology, Bio Med, Hualan Biological Engineering, Imunoloski Zavod, JN International Medical, Nuron Biotech, Pfizer, Serum Institute of India, Vacunas Finlay

【レポートのキーワード】

髄膜炎菌ワクチン、製薬、モノ・ワクチン、コンビネーション・ワクチン

【調査方法】

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界の髄膜炎菌ワクチン市場(2014-2018)]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月09日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆